Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022)
Alkermes' (ALKS) quarterly Non-Current Deffered Revenue came in at $6.4 million in Q3 2022, down 50.25% year-over-year from $12.9 million in Q3 2021, and down 44.3% quarter-over-quarter from $11.5 million in Q4 2021.
Analysis
Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022) Analysis & Trends
Alkermes (ALKS) has reported Non-Current Deffered Revenue for 12 consecutive years, with $6.4 million the latest figure, recorded in Q3 2022.
- On a quarterly basis, Non-Current Deffered Revenue fell 50.25% year-over-year to $6.4 million in Q3 2022; TTM through Sep 2022 was $6.4 million, a 50.25% decrease from a year earlier, with the FY2021 full-year figure at $11.5 million, down 29.92% from the prior year.
- Non-Current Deffered Revenue was $6.4 million for Q3 2022 at Alkermes, down from $11.5 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $22.1 million in Q4 2019 and troughed at $5.0 million in Q3 2018.
- A 5-year average of $12.8 million and a median of $11.6 million in 2019 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue soared 131.69% in 2019 and plunged 50.25% in 2022, its largest moves.
- Over 5 years, Non-Current Deffered Revenue stood at $9.5 million in 2018, then soared by 131.69% to $22.1 million in 2019, then retreated by 25.7% to $16.4 million in 2020, then decreased by 29.92% to $11.5 million in 2021, then tumbled by 44.3% to $6.4 million in 2022.
- The last three Non-Current Deffered Revenue figures came in at $6.4 million (Q3 2022), $11.5 million (Q4 2021), and $12.9 million (Q3 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.92 Bn | 626.16 Bn | 17.26 Bn | - |
| 2 | AbbVie | 441.93 Bn | 435.36 Bn | 12.70 Bn | - |
| 3 | Merck | 365.88 Bn | 358.74 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.44 Bn | 45.05 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 8 | Incyte | 25.31 Bn | 20.78 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.45 Bn | 18.78 Bn | 683.80 Mn | - |
| 10 | Alkermes | 7.57 Bn | 6.91 Bn | 397.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 6.40 Mn |
| Dec 31, 2021 | 11.49 Mn |
| Sep 30, 2021 | 12.86 Mn |
| Jun 30, 2021 | 14.17 Mn |
| Mar 31, 2021 | 14.75 Mn |
| Dec 31, 2020 | 16.40 Mn |
| Sep 30, 2020 | 18.64 Mn |
| Jun 30, 2020 | 18.88 Mn |
| Mar 31, 2020 | 21.16 Mn |
| Dec 31, 2019 | 22.07 Mn |
| Sep 30, 2019 | 11.19 Mn |
| Jun 30, 2019 | 11.62 Mn |
| Mar 31, 2019 | 11.34 Mn |
| Dec 31, 2018 | 9.53 Mn |
| Sep 30, 2018 | 5.01 Mn |
| Jun 30, 2018 | 5.86 Mn |
| Mar 31, 2018 | 6.17 Mn |
| Dec 31, 2017 | 5.66 Mn |
| Sep 30, 2017 | 6.13 Mn |
| Jun 30, 2017 | 6.78 Mn |